Recombinant Human HSP47 His-tag Protein, CF

2 μg/lane of Recombinant Human HSP47 was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Bluestaining, showing a band at ~50 kDa under R conditions.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human HSP47 His-tag Protein, CF Summary

• Details of Functionality: Bioassay data are not available.
• Source: Chinese Hamster Ovary cell line, CHO-derived human HSP47 protein
  Ala19-Asp412, with a C-terminal 6-His tag
• Accession #: P50454
• N-terminal Sequence: Ala19
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 44 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 47-51 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris, NaCl and TCEP.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human HSP47 His-tag Protein, CF

• (collagen binding protein 1)
• Arsenic-transactivated protein 3
• AsTP3
• BERF-1
• CBP1
• CBP2
• CBP2RA-A47
• Cell proliferation-inducing gene 14 protein
• Collagen-binding protein
• colligen
• Colligin
• colligin-1
• colligin-2
• gp46
• HSP47
• HSP47serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47)
• member 1, (collagen binding protein 1)
• member 2
• member 2, (collagen-binding protein 2)
• OI10
• PPROM
• proliferation-inducing gene 14
• RA-A47
• rheumatoid arthritis antigen A-47,47 kDa heat shock protein
• Rheumatoid arthritis-related antigen RA-A47
• serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47)
• Serpin H1
• serpin peptidase inhibitor, clade H (heat shock protein 47), member 1
• SERPINH1
• SERPINH2colligin

Background

Heat Shock Protein 47 (HSP47), also known as Serpin-H1, is a 47 kDa collagen-binding stress protein localized in the endoplasmic reticulum (ER) of collagen-secreting cells (1). It is encoded by the SERPINH1 gene, belongs to the serpin family, and contains the typical serpin fold but has no serine protease inhibitory activity (1). Human HSP47 shares 96% aa sequence identity with mouse HSP47. HSP47 is a chaperone that specifically binds pro-collagens at a neutral pH via Gly-Xaa-Arg repeats located on triple-helical procollagen to prevent aggregate formation (2). HSP47 is required for correct procollagen folding in the ER (1). Expression of HSP47 is directly correlated with expression of collagens in multiple types of cells and tissues. Gene disruption of HSP47 in mice causes embryonic lethality due to defects in collagen biosynthesis (1, 3) and HSP47-knockout cells show abnormal helix formation resulting in thin, branched fibrils (1, 4). HSP47 is associated with collagen-related disorders such as osteogenesis imperfecta (5) and fibrosis of the liver, lung, and other organs (6, 7). Its role in collagen regulation, as well as its ability to cause ER stress-mediated apoptosis in collagen-producing cells (6), make HSP47 a promising target for treatment in collagen-related diseases (7, 8). Additionally, HSP47 modulates the tumor microenvironment (9) and may serve as a predictive marker in patients with colorectal, renal, and laryngeal squamous cell carcinomas (10-12).

1. Ito S. and Nagata K. (2017) Seminars in Cell & Developmental Biology. 62:142.
2. Widmer, C. et al. (2012) Proc. Natl. Am. Soc. 109:13243.
3. Nagai N. et al. (2000) J. Cell Biol., 150: 1499.
4. Matsuoka Y. et al. (2004) Mol. Biol. Cell, 15: 4467.
5. Christiansen, H. E. et al. (2010) Am. J. Hum. Genet. 86:389.
6. Kawasaki, K. et al. (2015) J. Biol. Chem. 290:3639.
7. Ito, S. et al. (2017) J. Biol. Chem. 292:20076.
8. Otsuka, M. et al. (2017) Exp. Lung Res. 43:271.
9. Jiang X. et al. ACS Chem Neurosci. (2017) 8:128.
10. Mori K. et al. (2017) Int J Cancer. 140: 1425.
11. Song, X. et al. (2017) Oncol. Rep. 38:2444.
12. Qi, Y. et al. (2018) J. Cell Mol. Med. 22:1224.

Publications for Hsp47 (9166-SH)(1)

Publication using 9166-SH

• Xiao, H;Yao, Z;Li, T;Fang, X;Xu, X;Hu, S;Yang, Y;Jin, C;Fei, Y;Liu, C;Du, Q; SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway International immunopharmacology 2025-02-12 [PMID: 39946769] (Bioassay, Human)

Bioinformatics

• Uniprot:
  • P50454()